Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Healthtrust
Merck
Express Scripts
Queensland Health
Moodys

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,252,813

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,252,813 protect, and when does it expire?

Patent 8,252,813 protects BAXDELA and is included in two NDAs.

This patent has seven patent family members in five countries.

Summary for Patent: 8,252,813
Title:Salt and crystalline forms thereof of a drug
Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Inventor(s): Zhang; Geoff G. Z. (Libertyville, IL), Bradley; Michael F. (Covington, WA), Barnes; David M. (Lake Villa, IL), Henry; Rodger (Wildwood, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:12/701,254
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,252,813

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes   Try a Free Trial   Try a Free Trial Y TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS   Try a Free Trial
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes   Try a Free Trial   Try a Free Trial Y TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,252,813

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2582954   Try a Free Trial
European Patent Office 1802607   Try a Free Trial
European Patent Office 3056492   Try a Free Trial
Japan 2008515910   Try a Free Trial
Japan 5294633   Try a Free Trial
Mexico 2007004111   Try a Free Trial
World Intellectual Property Organization (WIPO) 2006042034   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Citi
Merck
US Army
UBS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.